干细胞对支气管肺发育不良的影响

Keeghan Andrews, V. Gallicchio
{"title":"干细胞对支气管肺发育不良的影响","authors":"Keeghan Andrews, V. Gallicchio","doi":"10.52793/jscr.2022.3(1)-04","DOIUrl":null,"url":null,"abstract":"Bronchopulmonary dysplasia (BPD) affects over 15,000 infant births per year in the United States and is one of the major causes of mortality in preterm infants. BPD is one of the most common long-term adverse effects from premature infant birth. Unlike other medical complications related to premature infant birth, the incidence of BPD is not declining. Approximately 15 million infants are born prematurely each year. One million infants worldwide are reported to die each year as a result of medical complications due to premature birth. Therapeutic interventions for BPD include: maternal progesterone, antenatal steroids, surgical cerclage, decreased ventilation levels, caffeine/methylxanthines, diuretics, bronchodilators, postnatal steroids, vitamin A, and inhaled nitric oxide. These interventions have demonstrated limited effectiveness. Mesenchymal stem cells (MSCs) are the preferred source for therapy for infants with BPD as they differentiate into various cell types including: muscles, bones, fat, and cartilage. Stem cell transplantation has shown to improve lung function and repair, decrease pulmonary hypertension, decrease risk for neurodevelopmental disorders, decrease BPD severity, and increase survival rates. Researchers believe the use of stem cells may offer alternative options for patients with BPD to improve lung function and decrease complications related to premature birth. potential BMSCs in a hyperoxia-induced model of BPD in rats. Results showed chronic hyperoxia in newborn rats led to loss of lung capillaries, air space enlargement, and decreased resident lung BMSCs. Administration of BMSCs on postnatal day 4 revealed decreased alveolar and lung vascular injury, improved survival and exercise tolerance, and decreased pulmonary hypertension. suggested for of hUSMSCs at 10 days of life. Six infants received a low dose of hUSCMSCs and 6 infants received a high dose of hUSCMSCs. Results of the study revealed no significant clinical differences between low dose and high dose groups. The treatment was tolerated and appeared to be safe. Additional research was recommended with a larger randomized controlled blinded study This study will evaluate monitor long term outcomes of therapy using neurological development tests and growth measures and compare hUCMSCs intervention with a placebo group. Sixty-two premature infants with BPD have been enrolled in this study. Each infant received a single intratracheal administration of hUCMSCs. Follow up assessments will be completed at: 6 months, 12 months, 18 months, 24 months, 36 months, 48 months, and 60 months. Several medical and clinical factors will be assessed and monitored: medical treatments including use of oxygen, steroids, bronchodilators, admissions to emergency room due to respiratory issues, survival rate, growth measured by percentile charts, neurological development measured by the Bayley Scale of Infant and Toddler Development, motor development measured by Gross Motor Function Classification System for Cerebral Palsy, incidence of deafness or blindness, number of adverse events, significant changes in physical exam, and brain MRI results. Patient data collection dates: January 2014 through March 2020. Clinical Trials.gov ID NCT01897987 3+3+3","PeriodicalId":92258,"journal":{"name":"Journal of stem cell research","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2022-02-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"The Effect Of Stem Cells On Bronchopulmonary Dysplasia\",\"authors\":\"Keeghan Andrews, V. Gallicchio\",\"doi\":\"10.52793/jscr.2022.3(1)-04\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Bronchopulmonary dysplasia (BPD) affects over 15,000 infant births per year in the United States and is one of the major causes of mortality in preterm infants. BPD is one of the most common long-term adverse effects from premature infant birth. Unlike other medical complications related to premature infant birth, the incidence of BPD is not declining. Approximately 15 million infants are born prematurely each year. One million infants worldwide are reported to die each year as a result of medical complications due to premature birth. Therapeutic interventions for BPD include: maternal progesterone, antenatal steroids, surgical cerclage, decreased ventilation levels, caffeine/methylxanthines, diuretics, bronchodilators, postnatal steroids, vitamin A, and inhaled nitric oxide. These interventions have demonstrated limited effectiveness. Mesenchymal stem cells (MSCs) are the preferred source for therapy for infants with BPD as they differentiate into various cell types including: muscles, bones, fat, and cartilage. Stem cell transplantation has shown to improve lung function and repair, decrease pulmonary hypertension, decrease risk for neurodevelopmental disorders, decrease BPD severity, and increase survival rates. Researchers believe the use of stem cells may offer alternative options for patients with BPD to improve lung function and decrease complications related to premature birth. potential BMSCs in a hyperoxia-induced model of BPD in rats. Results showed chronic hyperoxia in newborn rats led to loss of lung capillaries, air space enlargement, and decreased resident lung BMSCs. Administration of BMSCs on postnatal day 4 revealed decreased alveolar and lung vascular injury, improved survival and exercise tolerance, and decreased pulmonary hypertension. suggested for of hUSMSCs at 10 days of life. Six infants received a low dose of hUSCMSCs and 6 infants received a high dose of hUSCMSCs. Results of the study revealed no significant clinical differences between low dose and high dose groups. The treatment was tolerated and appeared to be safe. Additional research was recommended with a larger randomized controlled blinded study This study will evaluate monitor long term outcomes of therapy using neurological development tests and growth measures and compare hUCMSCs intervention with a placebo group. Sixty-two premature infants with BPD have been enrolled in this study. Each infant received a single intratracheal administration of hUCMSCs. Follow up assessments will be completed at: 6 months, 12 months, 18 months, 24 months, 36 months, 48 months, and 60 months. Several medical and clinical factors will be assessed and monitored: medical treatments including use of oxygen, steroids, bronchodilators, admissions to emergency room due to respiratory issues, survival rate, growth measured by percentile charts, neurological development measured by the Bayley Scale of Infant and Toddler Development, motor development measured by Gross Motor Function Classification System for Cerebral Palsy, incidence of deafness or blindness, number of adverse events, significant changes in physical exam, and brain MRI results. Patient data collection dates: January 2014 through March 2020. Clinical Trials.gov ID NCT01897987 3+3+3\",\"PeriodicalId\":92258,\"journal\":{\"name\":\"Journal of stem cell research\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2022-02-22\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of stem cell research\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.52793/jscr.2022.3(1)-04\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of stem cell research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.52793/jscr.2022.3(1)-04","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

支气管肺发育不良(BPD)每年影响美国15000多名婴儿的出生,是早产儿死亡的主要原因之一。BPD是早产儿最常见的长期不良反应之一。与其他与早产相关的医疗并发症不同,BPD的发病率并没有下降。每年约有1500万婴儿早产。据报道,全球每年有100万婴儿死于早产引起的并发症。BPD的治疗干预措施包括:母体孕酮、产前类固醇、外科环扎术、降低通气水平、咖啡因/甲基黄嘌呤、利尿剂、支气管扩张剂、产后类固醇、维生素A和吸入一氧化氮。这些干预措施的效果有限。间充质干细胞(MSC)是治疗婴儿BPD的首选来源,因为它们可以分化为各种细胞类型,包括:肌肉、骨骼、脂肪和软骨。干细胞移植已被证明可以改善肺功能和修复,降低肺动脉高压,降低神经发育障碍的风险,降低BPD的严重程度,并提高生存率。研究人员认为,干细胞的使用可能为BPD患者提供其他选择,以改善肺功能并减少与早产相关的并发症。高氧诱导的大鼠BPD模型中潜在的BMSC。结果显示,新生大鼠的慢性高氧导致肺毛细血管损失、空气间隙增大,并导致常驻肺BMSCs减少。出生后第4天给予BMSCs显示肺泡和肺血管损伤减少,存活率和运动耐受性提高,肺动脉高压降低。建议hUSMSCs在生命的10天。6名婴儿接受了低剂量hUSCMSCs,6名婴儿则接受了高剂量hUSCMSC。研究结果显示,低剂量组和高剂量组之间没有显著的临床差异。这种治疗是可以忍受的,看起来是安全的。建议进行更大规模的随机对照盲法研究。该研究将使用神经发育测试和生长测量来评估监测治疗的长期结果,并将hUCMSC干预与安慰剂组进行比较。62名患有BPD的早产儿被纳入本研究。每个婴儿接受一次hUCMSC的气管内给药。随访评估将在6个月、12个月、18个月、24个月、36个月、48个月和60个月完成。将评估和监测几个医疗和临床因素:医疗治疗,包括氧气、类固醇、支气管扩张剂的使用、因呼吸问题进入急诊室、存活率、百分位数图测量的生长、贝利婴幼儿发育量表测量的神经发育,通过脑瘫总运动功能分类系统测量的运动发育、耳聋或失明的发生率、不良事件的数量、体检的显著变化以及大脑MRI结果。患者数据收集日期:2014年1月至2020年3月。Clinical Trials.gov ID NCT01897987 3+3+3
本文章由计算机程序翻译,如有差异,请以英文原文为准。
The Effect Of Stem Cells On Bronchopulmonary Dysplasia
Bronchopulmonary dysplasia (BPD) affects over 15,000 infant births per year in the United States and is one of the major causes of mortality in preterm infants. BPD is one of the most common long-term adverse effects from premature infant birth. Unlike other medical complications related to premature infant birth, the incidence of BPD is not declining. Approximately 15 million infants are born prematurely each year. One million infants worldwide are reported to die each year as a result of medical complications due to premature birth. Therapeutic interventions for BPD include: maternal progesterone, antenatal steroids, surgical cerclage, decreased ventilation levels, caffeine/methylxanthines, diuretics, bronchodilators, postnatal steroids, vitamin A, and inhaled nitric oxide. These interventions have demonstrated limited effectiveness. Mesenchymal stem cells (MSCs) are the preferred source for therapy for infants with BPD as they differentiate into various cell types including: muscles, bones, fat, and cartilage. Stem cell transplantation has shown to improve lung function and repair, decrease pulmonary hypertension, decrease risk for neurodevelopmental disorders, decrease BPD severity, and increase survival rates. Researchers believe the use of stem cells may offer alternative options for patients with BPD to improve lung function and decrease complications related to premature birth. potential BMSCs in a hyperoxia-induced model of BPD in rats. Results showed chronic hyperoxia in newborn rats led to loss of lung capillaries, air space enlargement, and decreased resident lung BMSCs. Administration of BMSCs on postnatal day 4 revealed decreased alveolar and lung vascular injury, improved survival and exercise tolerance, and decreased pulmonary hypertension. suggested for of hUSMSCs at 10 days of life. Six infants received a low dose of hUSCMSCs and 6 infants received a high dose of hUSCMSCs. Results of the study revealed no significant clinical differences between low dose and high dose groups. The treatment was tolerated and appeared to be safe. Additional research was recommended with a larger randomized controlled blinded study This study will evaluate monitor long term outcomes of therapy using neurological development tests and growth measures and compare hUCMSCs intervention with a placebo group. Sixty-two premature infants with BPD have been enrolled in this study. Each infant received a single intratracheal administration of hUCMSCs. Follow up assessments will be completed at: 6 months, 12 months, 18 months, 24 months, 36 months, 48 months, and 60 months. Several medical and clinical factors will be assessed and monitored: medical treatments including use of oxygen, steroids, bronchodilators, admissions to emergency room due to respiratory issues, survival rate, growth measured by percentile charts, neurological development measured by the Bayley Scale of Infant and Toddler Development, motor development measured by Gross Motor Function Classification System for Cerebral Palsy, incidence of deafness or blindness, number of adverse events, significant changes in physical exam, and brain MRI results. Patient data collection dates: January 2014 through March 2020. Clinical Trials.gov ID NCT01897987 3+3+3
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信